Merrimack Pharmaceuticals, Inc. (MACK)
| Market Cap | 179.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.68M |
| Shares Out | 14.26M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,339 |
| Open | 12.68 |
| Previous Close | 12.67 |
| Day's Range | 12.55 - 12.69 |
| 52-Week Range | 3.00 - 13.66 |
| Beta | 1.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 4, 2023 |
About MACK
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. [Read more]
Financial Performance
Financial StatementsNews
Merrimack College Teacher Survey Highlights Troubling K-12 Teacher Morale Issues
NORTH ANDOVER, Mass.--(BUSINESS WIRE)--A newly released study shines a spotlight on a pressing crisis facing American education: Only 46% of current public K-12 educators would be “fairly” or “very li...
Merrimack Reports First Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 3...
Merrimack Reports Full Year 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, ...
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has extended the Section 3...
Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment
Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% I...
Merrimack Reports Third Quarter 2022 Financial Results
CAMBRIDGE, Mass.
Merrimack Reports Second Quarter 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2022 Financial Results
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Provides Ipsen report of results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer
Merrimack Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 3...
Merrimack Reports Full Year 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2021 Financial Results
Merrimack Reports Third Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Reports Third Quarter 2021 Financial Results
Merrimack Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, ...
Merrimack Reports Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results
Merrimack Reports Third Quarter 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release
Merrimack Reports Second Quarter 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2020 Financial Results